Zusammenfassung
Aufgrund der demographischen Entwicklung ist in Europa und Nordamerika eine Zunahme der altersabhängigen Makuladegeneration (AMD) zu beobachten. Sie ist eine der führenden Ursachen für Blindheit und stellt gleichzeitig ein großes ökonomisches Problem dar.
Es gibt zahlreiche Hinweise, dass oxidativer Stress die Entwicklung der AMD begünstigt. Da das energiereiche blaue Licht an der neurosensorischen Netzhaut zu photooxidativen Schäden führen kann, ist das makuläre Pigment (MP) durch seinen Filtereffekt und seine antioxidative Wirkung für den Schutz der zentralen Netzhaut von hoher Bedeutung und wird oft als „natürliche Sonnenbrille“ bezeichnet. Das MP ist biochemisch eine Anreicherung von Lutein und Zeaxanthin. Diese Mikronährstoffe, genauso wie Vitamine mit antioxidativer Wirkung (vor allem Vitamin C, E und β-Karotin) können von Säugetieren nicht synthetisiert werden. Deswegen wird die Bedeutung der Ernährung bzw. der Supplementation für die Entstehung und Progression der AMD schon seit Jahren diskutiert.
Die Ergebnisse der bisher publizierten Studien, die den Zusammenhang zwischen MP und AMD untersuchten, sind widersprüchlich. Ein positiver Einfluss der Supplementation von Lutein und Zeaxanthin wurde bis jetzt in keiner randomisierten placebokontrollierten Studie nachgewiesen. Die therapeutische Beeinflussung der AMD durch einen erhöhten Konsum von Antioxidantien und ω-3-Fettsäuren (die in Meeresfischen vorkommen) wurde in den diesen Studien kontrovers bewertet.
Die bis jetzt größte abgeschlossene randomisierte placebokontrollierte Studie, die einen signifikanten Einfluss der Supplementation von Antioxidantien, Zink und Kupfer auf bestimmte Formen der AMD nachwies, ist die ARED Studie. Sie empfiehlt diese Supplementation nur für klar definierte Risikogruppen. Die Gabe von Lutein und ω-3-Fettsäuren ist nicht toxisch, aber bisher nicht durch randomisierte Studien abgesichert.
Abstract
Demographic developments in Europe and North America are causing an increase of age-related diseases. Age-related macular degeneration (AMD) is one of the leading causes of severe central visual acuity loss in elderly people and seems to be an economic problem, too. There is evidence that oxidative damage is an important factor for exacerbation of AMD. Macular pigment with its antioxidative effect may serve as“natural sunglasses” filtering the blue light acting as a possible source of photooxidative damage to the neurosensory retina. The macular pigment consists mostly of lutein and zeaxanthin. These micronutrients from the group of carotenoids, as is the case for vitamins (vitamins C, E, and β-carotene), cannot be synthesized in mammals and that is the reason why the role of micronutrition or its supplementation and its correlation to AMD progression has been discussed for years.
The results of currently published studies are often contradictory. At present there are no results from randomized controlled studies confirming that supplementation of lutein and zeaxanthin can reduce the risk for AMD. Several epidemiological studies investigating the impact of antioxidants and ω-3 fatty acids on the incidence of AMD provided conflicting results.
Up to now, AREDS is the largest randomized controlled study investigating the effect of supplementation of antioxidants, zinc, and copper on the progression of AMD. AREDS showed a significant effect of this supplementation in some particular groups of patients with AMD. The supplementation of lutein and ω-3 fatty acids is not toxic but a positive effect has not been proven by randomized studies.
Abbreviations
- AMD:
-
Altersabhängige Makuladegeneration, „age-related macular degeneration“
- ARED(S):
-
Age-Related Eye Disease (Study)
- ARM:
-
Age-related maculopathy
- CNV:
-
Choroidale Neovaskularisationen
- CuO:
-
Kupferoxid
- DGE:
-
Deutsche Gesellschaft für Ernährung
- DHA:
-
Docosahexaensäure
- EDCCS:
-
Eye Disease Case-Control Study
- EPA:
-
Eicosapentaensäure
- GRAS:
-
Generally recognised as safe
- L:
-
Lutein
- LAST:
-
Lutein Antioxidant Supplementation Trial
- MP:
-
Makuläres Pigment
- MPD:
-
Makulapigmentdichte
- POLA:
-
Pathologies Oculaires Liées à l’Age
- RPE:
-
Retinales Pigmentepithel
- USDA:
-
United States Department of Agriculture
- VECAT:
-
Vitamin E, Cataract, and Age-related Maculopathy Trial
- Vit.:
-
Vitamin
- XBP:
-
Xanthophyll-binding-Protein
- Z:
-
Zeaxanthin
- ZnO:
-
Zinkoxid
Literatur
Age-Related Eye Disease Study Research Group (1996) Multicenter ophthalmic and nutritional age-related macular degeneration study-part 1: design, subjects and procedures. J Am Optom Assoc 67: 12–29
Age-Related Eye Disease Study Research Group (2001) AREDS Report No.8 – A randomized, Placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 119: 1417–1436
Age-Related Eye Disease Study Research Group (2004) AREDS Report No.18 – A simplified severity scale for age-related macular degeneration. Arch Ophthalmol 123: 1570–1574
Ahmend SS, McGregor NL, Marcus DM (2005) The macular Xanthophylls. Surv Ophthalmol 50: 183–193
Alves-Rodrigues A, Shao A (2004) The science behind Lutein. Toxicol Lett 150: 57–83
Augood CA, Jong PT de, Chakravathy U et al. (2006) Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EU-REYE). Arch Ophthalmol 124: 529–535
Augustin AJ, Schmidt-Erfurth U (2002) Critical comments on the ARED study. Ophthalmologe 99: 299–300
Beatty S, Koh H, Phil M et al. (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45: 115–134
Beatty S, Murray IJ, Henson DB et al. (2001) Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 42: 439–446
Berendschot TT, Willemse-Assink JJ, Bastiaanse M et al. (2002) Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 43: 1928–1932
Bernstein PS, Zhao DY, Wintch SW et al. (2002) Resonance Raman measurement of macular carotenoids in normal subjects and in age-related macular degeneration patients. Ophthalmology 109: 1780–1787
Biesalski HH (2007) Antioxidanzien – kein Grund zur Neubewertung. Ophthalmologe (online 27.6.2007; 10.1007/s00347–007–1579–9)
Bird AC, Bressler NM, Bressler SB et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM Epidemiological Study Group. Surv Ophthalmol 39: 367–374
Bjelakovic G, Nikolova D, Gluud LL et al. (2007) Mortality in randomized trials of antioxidant supplements for primary and secondary prevention. JAMA 297: 842–857
Bone RA, Landrum JT (1984) Macular pigment in Henle fiber membranes: a model for Haidinger’s brushes. Vision Res 24: 103–108
Bone RA, Landrum JT, Fernandez et al. (1988) Analysis of the macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci 29: 843–849
Bone RA, Landrum JT, Guerra LH et al. (2003) Lutein and zeaxanthin dietary supplements raise macular pigment density and serum contcentration of these carotenoids in humans. J Nutr 133: 992–998
Cardinault N, Abalain JH, Sairafi B et al. (2005) Lycopene but not lutein nor zeaxanthin decreases in serum and lipoproteins in age-related macular degeneration patients. Clin Chim Acta 357: 34–42
Cho E, Hung S, Willett WC et al. (2001) Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 73: 209–218
Cho E, Seddon JM, Rosner WCW et al. (2004) Prospective study of intake of fruits, vegetables, vitamins and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 122: 883–892
Ciulla TA, Curran-Celantano J, Cooper DA (2001) Macular pigment optical density in a midwestern sample. Ophthalmology 108: 730–737
Connor KM, Sangiovanni JP, Lofqvist C et al. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13: 868–873
Cruickshanks KJ, Klein R, Klein BEK et al. (1995) Sunlight and age-related macular degeneration. Arch Ophthalmol 111: 514–518
Dasch B, Fuhs A, Schmidt J (2005) Serum levels of macular carotenoids in relation to age-related maculopathy: the Muenster Aging and Retina Study (MARS). Graefes Arch Clin Exp Ophthalmol 243: 1028–1035
Delcourt C, Diaz JL, Ponton-Sanchez A et al. (1998) Smoking and age-related macular degeneration. Arch Ophthalmol 116: 1031–1035
Delcourt C, Cristol JP, Tessier F et al. (1999) Age-related degeneration and antioxidant status in the POLA Study. Arch Ophthalmol 117: 1384–1390
Doenecke D, Koolman J, Fuchs G et al. (2005) Karlsons Biochemie und Pathobiochemie. Thieme, Stuttgart New York, S 336–338
Edwards AO, Ritter R 3rd, Abel KJ et al. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421–424
Evans JR (2001) Risk factors for age-related macular degeneration. Prog Retin Eye Res 20: 227–253
Evans JR (2006) Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 19: CD000254
Evans JR, Fletcher AE, Wormald RPL (2005) 28000 cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br J Ophthalmol 89: 550–553
Flood V, Smith W, Wang JJ et al. (2002) Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 109: 2272–2278
Garrett SK, Thomas AP, Cicuttini F et al. (2000) Community-based recruitment strategies for a longitudinal interventional study: the VECAT experience. J Clin Epidemiol 53: 541–548
Hammond BR, Caruso-Avery M (2000) Macular pigment optical density in a Southwestern sample. Invest Ophthalmol Vis Sci 41: 1492–1497
Hammond BR Jr, Fuld K, Curran-Celentano J (1995) Macular pigment density in monozygotic twins. Invest Ophthalmol Vis Sci 36: 2531–2541
Hammond BR Jr, Johnson EJ, Russel R et al. (1997) Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci 38: 1795–1801
Hayes KC (1974) Retina degeneration in monkeys induced by deficiency of vitamin E or A. Invest Ophthalmol Vis Sci 13: 499–510
Hogg R, Chakravathy U (2004) AMD and micronutrient antioxidants. Curr Eye Res 29: 387–401
Hodge WG, Schachter HM, Barnes D et al. (2006) Efficacy of ω-3 fatty acids in preventing age-related macular degeneration. Ophthalmology 113: 1165–1173
Holz FG, Wolfensberger TJ, Piguet B et al. (1993) Oral zinc and the second second eye in age-related macular degeneration: A double blind study. Ger J Ophthalmol 2: 391
Jahn C, Brinkmann C, Mößner A et al. (2006) Jahreszeitliche Schwankungen und Einfluss der Ernährung auf die makuläre Pigmentdichte. Ophthalmologe 103: 136–140
Johnson EJ (2005) Obesity, lutein metabolism, and age-related macular degeneration: a web of connections. Nutr Rev 63: 9–15
Kahn HA, Leibowitz HM, Ganley JP et al. (1977) The Framingham Eye Study. II. association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 106: 33–41
Kaiser HJ, Flammer J, Stumpfig D et al. (1995) Visaline in the treatment of age-related macular degeneration: A pilot study. Ophthalmologica 209: 302–305
Klein R, Davis MD, Magli YL et al. (1991) Wisconsin age-related maculopathy grading system. Ophthalmology 98: 1128–1134
Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Study. Ophthalmology 99: 933–943
Landrum JT, Bone RA, Joa H et al. (1997) A one year study of macular pigment: The effect of 140 days of lutein supplement. Exp Eye Res 65: 57–62
Mares-Perlman JA, Brady WE, Klein R et al. (1995) Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol 113: 1518–1523
Mares-Perlman JA, Fisher AI, Palta M et al. (2001) Lutein and Zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 153: 424–432
Mares-Perlman JA, Millen AE, Ficek TL et al. (2002) The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. Overview. J Nutr 132: 518S–524S
Mitchell P, Wang JJ, Smith W et al. (2002) Smoking and the 5-year incidence of age-related maculopathy. The Blue Mountains Eye Study. Arch Ophthalmol 120: 1357–1363
Newsome DA, Swartz M, Leone NC et al. (1988) Oral zinc in macular degeneration. Arch Ophthalmol 106: 192–198
Omenn GS, Goodman GE, Thornquist MD et al. (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150–1155
Pauleikhoff D, Koch JM (1995) Prevalence of age-related macular degeneration. Curr Opin Ophthalmol 6: 51–56
Richer S (1996) Multicenter ophthalmic and nutritional age-related macular degeneration study–part 2: antioxidant intervention and conclusions. J Am Optom Assoc 67: 30–49
Richer SP (1993) Is there a prevention and treatment strategy for macular degeneration? J Am Optom Assoc 64: 838–850
Richer SP, Stiles W, Statkute L et al. (2004) Double-masked, placebo-controlled, randomized trial of Lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 75: 216–230
Robman LD, Tikellis G, Garrett SK (1999) Baseline ophthalmic findings in the vitamin E, cataract and age-related maculopathy (VECAT) study. Aust N Z J Ophthalmol 27: 410–416
Scholl HP, Fleckenstein M, Issa PC et al. (2007) An update on the genetics of age-related macular degeneration. Mol Vis 13: 196–205
Schmidt-Erfurth U (2005) Nutrition and retina. Dev Ophthalmol 38: 120–147
Schrader WF (2006) Altersbedingte Makuladegeneration. Sozioökonomische Zeitbombe in der alternden Gesellschaft. Ophthalmologe 103: 742–748
Seddon JM, Alani UA, Sperduto RD et al. (1994) Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272: 1413–1420
Seigel D (2002) AREDS investigators distort findings. Arch Ophthalmol 120: 100–101
Snellen EL, Verbeek AL, Van Den Hoogen GW (2002) Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand 80: 368–371
Snodderly DM (1995) Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr 62: 1448S–1461S
Snodderly DM, Auran JD, Delori FC (1984) The macular pigment. II. Spatial distribution in primate retinas. Invest Ophthalmol Vis Sci 25: 674–683
Stur M, Tittl M, Reitner A et al. (1996) Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci 37: 1225–1235
Suner IJ, Espinosa-Heidmann DG, Marin-Castano ME, Hernandez et al. (2004) Nicotine increases size and severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 45: 311–317
Taylor HR, West S, Munoz B et al. (1994) The long-term effects of visible light on the eye. Arch Ophthalmol 110: 99–104
Tan JS, Mitchell P, Smith W et al. (2007) Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology114: 143–150
Thomson LR, Toyoda Y, Langner A et al. (2002) Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest Ophthalmol Vis Sci 43: 3538–3549
Trieschmann M, Beatty S, Nolan JM et al. (2007) Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: The LUNA study. Exp Eye Res 84: 718–28; Epub 2006 Dec
VandenLagenberg GM, Mares-Perlman JA, Klein R et al. (1998) Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 148: 204–214
Leeuwen R van, Boekhoorn S, Vingerling JR et al. (2005) Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 294: 3101–3107
Vingerling JR, Dielemans I, Hofman A et al. (1995) The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102: 205–210
Wald G (1949) The photochemistry of vision. Doc Ophthalmol 3: 94–137
Werner JS, Donnelly SK, Kliegl R (1987) Aging and human macular pigment density: appended with translations from the work of Max Schultze and Ewald Hering. Vision Res 27: 257–268
Wooten BR, Hammond BR (2002) Macular pigment: influences on visual acuity and visibility. Prog Retin Eye Res 21: 225–240
Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122: 598–6144
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rehak, M., Fric, E. & Wiedemann, P. Lutein und Antioxidantien zur Prävention der AMD. Ophthalmologe 105, 37–45 (2008). https://doi.org/10.1007/s00347-007-1602-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-007-1602-1